Merck reports Q2 2026 adjusted loss per share of 13 cents, beating estimate of 23 cents loss; raises full-year adjusted EPS guidance to $2.66–$2.76 from prior $5.04–$5.16.
LiveSquawk08/04, 06:09 PM
- Adj Loss/SHR 13C
- Est Loss/SHR 23C
- Sales $16.61B
- Est $16.35B
Figures as quoted by LiveSquawk